EnteroBiotix celebrates success at UK emerging entrepreneur of the year awards

Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that the Company’s CEO, James McIlroy, was awarded the title of ‘Emerging Entrepreneur of the Year’ at the 2017 BQ National Entrepreneur Festival.

Hosted by BQ and powered by Atom Bank, the awards brought together entrepreneurs from across the UK with the challenge of identifying individuals who, in the view of the judges, are part of the next generation of successful entrepreneurs.

The Scottish award was supported by Scottish Institute for Enterprise. CEO Fiona Godsman said:

“Scotland’s historic contribution to innovation both in the UK and the wider world is widely known. We’re very proud of the next generation of Scottish innovators at SIE and we’re very pleased to help showcase some of our brightest new talent on the national stage. The Scottish winner, James McIlroy, is an excellent example of someone using entrepreneurship to solve a real problem. He’s made great strides with EnteroBiotix which has already gained significant traction and investment”

For further information, please see the official article on the BQ Website.

About EnteroBiotix
EnteroBiotix is harnessing the human microbiome to develop novel medicinal products that restore health and prevent disease. The company’s first focus is to unlock the full therapeutic potential intestinal microbiome transfer through two core product portfolios targeting gastrointestinal diseases and infections caused by bacteria such as C.difficile. EnteroBiotix has established deep operational experience and capabilities, including fully integrated ISO-accredited microbial collection and GMP-compliant clean room manufacturing facilities under a manufacturer’s specials license (License Number: MS 49464) and an MIA (IMP) license (License Number: MIA(IMP) 49464) from the Medicines and Healthcare Products Regulatory Agency (MHRA). Since its formation in March 2017, EnteroBiotix has raised over £2.5m in seed investment and has distributed its market entry, minimally manipulated medicinal products on a named patient basis around Europe. EnteroBiotix has offices in Aberdeen, Scotland, and Boston, USA.

For further information, please contact:

James McIlroy, CEO